Navigation Links
Stallergenes Inaugurates the Biggest Pharmaceutical Allergen Production Unit in the World
Date:9/10/2008

ANTONY, France, September 10 /PRNewswire-FirstCall/ -- Stallergenes S.A. officially inaugurates its new pharmaceutical production unit, located in the Paris area.

Designed to comply with the most stringent EMEA (European Medicines Agency) and FDA (US Food and Drug Administration) standards, this unit will produce desensitisation treatments for all markets, primarily in Europe and North America.

This investment worth more than 20 million euros will incorporate the production of the active substance for the Oralair(R) Grasses tablet and increase the production capacity for Staloral(R), to meet the needs of an expanding international marketplace.

"For Stallergenes, this investment marks a major step forward. This new production unit will help the company break into the tough U.S market and increase its production capacity tenfold," states Albert Saporta, Chairman and CEO of Stallergenes.

ABOUT ORALAIR(R) GRASSES

Oralair(R) Grasses is a fast-dissolving sublingual desensitisation tablet indicated in allergic rhino-conjunctivitis caused by grass pollen for patients with moderate to severe symptoms unsatisfied with or inadequately controlled by symptomatic treatments. Oralair(R) Grasses contains a mix of five standardised grass allergens, mimicking patients' natural exposure: perennial rye grass (Lolium perenne), meadow grass (Poa pratensis), timothy grass (Phleum pratense), cocksfoot (Dactylis glomerata) and sweet vernal grass (Anthoxanthum odoratum). In June 2008, Oralair(R) Grasses was granted a marketing authorisation in adults in Germany and a paediatric extension of its indications is expected by the end of the year. Stallergenes then plans to launch a mutual recognition procedure in the near future, with a view to marketing Oralair(R) Grasses in other European countries in both indications.

ABOUT Staloral(R)

Staloral(R) is an NPP (named patient product) sublingual solution (drops to be placed under the tongue) of allergen extracts. Staloral(R) is indicated in allergic rhino-conjunctivitis caused by pollen, dust mites, mould and dander (animal hair). Staloral(R) is available in the majority of European countries.

ABOUT STALLERGENES

Stallergenes is a European biopharmaceutical company dedicated to desensitisation therapies for the prevention and treatment of allergy-related respiratory diseases, e.g. rhino-conjunctivitis and allergic asthma. A pioneer and leader in sublingual desensitisation treatments, Stallergenes devotes 20% in raw data of its turnover to Research and Development and is actively involved in the development of a new therapeutic class: sublingual desensitisation tablets.

In 2007, Stallergenes had a turnover of 147 million euros and provided desensitisation treatments to more than 500,000 patients.

Stallergenes is listed on Euronext Paris (Compartment

B) and is part of the sample composing the SBF 120

index.

ISIN code: FR0000065674

Reuters code: GEN.PA

Bloomberg code: GEN.FP

To find out more, visit the website: http://www.stallergenes.com


'/>"/>
SOURCE Stallergenes
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Stallergenes: First Half Year 2008: A 19% Increase in Operating Profit and Net Profit
2. Stallergenes: Q2 2008 Sales up 18% Revision Upwards of 2008 Sales Growth
3. Stallergenes : Sublingual Desensitisation Tablets Oralair Grasses Approved in Germany
4. STALLERGENES : Further Profit Growth Acceleration of R&D Expenditure
5. STALLERGENES: 2007: A Further Year of Strong Growth: Up 16%
6. STALLERGENES and Protein eXpert Enter Into a Partnership for Producing Mites Recombinant Allergens
7. STALLERGENES: ORALAIR Grasses: Positive Results of VO52.06 Paediatric Study
8. Stallergenes : 3rd Quarter Sales Up 17%: 9- Month Cumulative Sales Up 17%
9. STALLERGENES : Strong Business Growth: +17% and Earnings Per Share up 30%
10. Eyeforpharmas Marketing Summit is shaping up to be the biggest event of its kind ever
11. Panacea Pharmaceuticals Lung Cancer Diagnostic Test, LC Detect(SM), Named One of Time Magazines Ten Biggest Medical Breakthroughs of 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... 2016 Eutilex Co. Ltd. today announced that ... Series A financing. This financing round included participation from ... SNU Bio Angel. This new funding brings the total ... $27.7M) since its founding in 2015. ... and commercialization of its immuno-oncology programs, expand its R&D ...
(Date:12/7/2016)... ... December 07, 2016 , ... A new ... the setting of previously treated, advanced pancreatic cancer, liquid biopsies are not yet ... population and timing of blood sampling may improve the value of a blood-based ...
(Date:12/7/2016)... CALGARY , Dec. 7, 2016 /PRNewswire/ - Zenith Capital Corp. ... update that will be presented at the Company,s Annual and ... Meeting of Shareholders will take place on Thursday, December 15, ... Ross Glenn Hall (Room EC1040), 4825 Mount Royal Gate ... am (MST). A notice of meeting and management information circular, ...
(Date:12/7/2016)... 7, 2016  Vyriad Inc. announced today the appointment ... Board of Directors. "We are delighted to ... business and develop our oncolytic viruses as the next ... Stephen Russell , MD, PhD, CEO of Vyriad. "Al ... vision and passion for making a difference for cancer ...
Breaking Biology Technology:
(Date:11/24/2016)... Nov. 23, 2016 Cercacor today introduced Ember ... their trainers non-invasively measure hemoglobin, Oxygen Content, ... and Respiration Rate in approximately 30 seconds. Smaller than ... and immediate access to key data about their bodies ... training regimen. Hemoglobin carries oxygen to ...
(Date:11/19/2016)... , Nov. 18, 2016 Securus Technologies, ... solutions for public safety, investigation, corrections and monitoring, announced ... smaller competitor, ICSolutions, to have an independent technology judge ... the most modern high tech/sophisticated telephone calling platform, and ... customers that they do most of what we do ...
(Date:11/15/2016)... 2016  Synthetic Biologics, Inc. (NYSE MKT: SYN), ... the gut microbiome, today announced the pricing of ... its common stock and warrants to purchase 50,000,000 ... to the public of $1.00 per share and ... the offering, excluding the proceeds, if any from ...
Breaking Biology News(10 mins):